New weight loss pill beats oral Ozempic in major trial
A new once-daily weight-loss pill called orforglipron delivered better weight loss and blood sugar improvements than the leading oral semaglutide in a major clinical trial. The tablet could offer a more convenient alternative to injectable drugs...
schedule
05:16 visibility
56 views
Source: Science Daily
A new once-daily weight-loss pill called orforglipron delivered better weight loss and blood sugar improvements than the leading oral semaglutide in a major clinical trial. The tablet could offer a more convenient alternative to injectable drugs like Ozempic and Wegovy because it doesn't require refrigeration or special timing with meals. It's also cheaper to manufacture, which could expand access globally.
Google's AI chip-equipped satellite has generated its first response from space. In a blog post on Friday, Google says it successfully booted up the satellite's Tensor Processing Units (TPUs), allowing the on-board Gemma 4 model to follow through on...
Modern smart TVs let you skip the streaming device, which is convenient, but they also come with their own issues, including privacy concerns and frequent updates. The Vizio Mini LED Quantum TV lets you cut out the rigamarole and just get straight...
In this edition of Access Asia, we explore why anti-Indian sentiment is rising in the United States in the wake of the foiled plot targeting a Hindu temple in Illinois. We ask the executive director of the Center for the Study of Organized Hate...
Premières manifestations, premiers débats, premiers engagements militants… Pour de nombreux jeunes, le mouvement lycéen coïncide avec une prise de conscience politique accrue qui transforme leur quotidien, à six mois d’une élection présidentielle à...
Today on Decoder, I’m joined by Joey Brookhart, an analyst at the chip and AI research firm SemiAnalysis, to help me dig into the story inside the numbers of the Anthropic IPO filing — a document known as an S-1. Anthropic just filed its S-1 to go...
The Verge
We use cookies to improve your experience. By continuing to use this site, you agree to our use of cookies. Learn more